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Abstract: More than 130 radionuclides are being used worldwide for therapeutic, diagnostic, and preventative purposes 
in the medical field. Using radionuclides, different organs can be imaged, and malfunction revealed. The most commonly 
used radionuclide in diagnosis by SPECT is technetium-99m (99mTc), with some 40 million procedures yearly, almost 
80% of all nuclear medicine procedures in the world. The Positron Emission Tomography (PET) is sophisticated and 
more precise technique using isotopes, like 18F produced in a cyclotron. The synthesis and use of organic molecules and 
their labeling with radionuclides are currently dominating in new radiopharmaceutical development. On the other hand 
inorganics (60Co, 131I and 192Ir) are still playing unique role in nuclear medicine. In this article more commonly used 
radionuclides and their inorganic forms in nuclear medicine are described. 
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1. INTRODUCTION 
In Nuclear medicine radiation is used to gain 
diagnostic information about the functioning of a 
patient's specific organs, or to cure them. The use of 
radionuclides in solution form began in the late 1930s 
with attempts to treat blood diseases such as 
polycythaemia vera with the aid of phosphorus-32 (32P) 
labeled sodium hydrogen phosphate [1]. At the same 
time, Iodine-131 (131I) as sodium iodide was being 
trialled as a treatment for cancer of thyroid [2]. Using 
gamma (γ) emitting radionuclides, various organs such 
as thyroid, bones, heart, brain, liver, spleen etc, are 
imaged, and malfunction in organ revealed. Radiation 
is also used to cure diseased organs, or tumours. Over 
ten thousand hospitals worldwide use radionuclides in 
medicine, and about 90% of the procedures are for 
diagnostic purposes. The most common radionuclide 
used in diagnosis is technetium-99m (99mTc); the 
daughter product of molybdenum-99 (99Mo). 
Approximately 40 million procedures are performed 
yearly, accounting for 80% of all nuclear medicine 
procedures worldwide [3]. Nuclear medicine was 
developed in the 1950s by physicians with an 
endocrine emphasis, initially using 131I to diagnose and 
then treat thyroid disorder [4]. The Positron Emission 
Tomography (PET) is a sophisticatedand, more 
accurate technique using isotopes produced in 
accelerators. PET is a functional imaging technique 
that produces a three-dimensional (3-D) image of 
functional processes in the human body. PET's most 
important clinical role is in oncology, with fluorine-18 
(18F) as the prime radiotracer, since it has proven to be 
the most accurate non-invasive method of  
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detecting and evaluating most cancers [5]. Several 
radionuclides have been developed and tagged into 
appropriate carriers for targeted radiotherapy and 
diagnosis. As radionuclide carriers, chelating chemical 
agents, monoclonal antibodies, peptides, biomolecules, 
biodegradable particles, colloids, etc., have been 
investigated as radiopharmaceuticals for therapeutic 
nuclear medicine. The synthesis and use of organic 
molecules and their labeling with different radionuclides 
are currently dominating in new radiopharmaceutical 
development [6]. On the other hand inorganics are still 
playing unique role in nuclear medicine [7]. Inorganics 
include metals, salts, compounds made from single 
elements and any other substance that don't contain 
carbon bonded to hydrogen. In this article more 
commonly used radionuclides and their inorganic forms 
in nuclear medicine are described. It includes decay 
characteristics, production mode and medical 
applications etc., of the radionuclides. 
2. RADIONUCLIDES FOR DIAGNOSIS AND 
THERAPY 
Radioisotopes are used in diagnostic studies via 
emission tomography (SPECT and PET). Diagnostic 
techniques use radiotracers which emit γ rays from 
within the body. These tracers are usually short-lived 
linked to chemical compounds which permit specific 
physiological functions to be checked. The radio 
labeled compounds are injected, inhaled or given 
orally. The first type is where single photons are 
detected by a γ-camera which can view certain organs 
from many different angles. In the second type a 
positron-emitting radionuclide is introduced, usually by 
injection, and accumulates in the target tissue. As it 
decays it emits a positron (β+), which promptly 
combines with a nearby electron resulting in the 
simultaneous emission of two identifiable γ rays (511 
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keV) in opposite directions. These are detected by a 
PET camera and give very accurate indication of their 
origin. 
The major criteria for the selection of a radionuclide 
for therapy are suitable decay characteristics and 
biochemical behavior. Regarding the decay properties, 
the desired half life is between few hours and several 
days; the emitted particles (β-, α, and Auger electron) 
of radiation should have an appropriate linear energy 
transfer (LET) value and range in the tissue. The ratio 
of target to non target tissue should be high. 
2.1. Boron Neutron Capture Therapy	  
In 1935, Taylor and Goldhaber described that 
boron-10 (10B) nuclei could capture thermal neutrons 
resulting in splitting of the boron-11 (11B) nuclei into 
helium-4 (α particles) and lithium-7(7Li) ions [8].  
10B + nth → [11B] → α + 7Li + 2.31 MeV 
In 1936, Locher, a scientist at the Franklin Institute 
in Pennsylvania, realized the therapeutic potential of 
the reaction and products and proposed that boron 
neutron capture could be used for the treatment of 
cancer [9, 10].  Sweet first suggested the discovery for 
the most malignant brain tumors in 1951[11], and a trial 
of the therapy against glioblastoma multiforme using 
borax (sodium borate) as the boronating agent was 
reported in a collaboration between Massachusetts 
General Hospital and Brookhaven National Laboratory 
in 1954 [12]. 
Both α particles and 7Li ions produce closely spaced 
ionizations in the immediate vicinity of the reaction, with 
a range of approximately 5–9 µm; the diameter of one 
cell. Their lethality is limited to 10B containing cells. 
Boron Neutron Capture Therapy (BNCT), therefore, 
can be considered as both a physically and biologically 
targeted type of radiation therapy. The success of 
BNCT is dependent upon the selective delivery of 
sufficient amounts of 10B to the tumor with only small 
amounts localized in the surrounding normal tissues 
[13]. Various 10B delivery agents have been 
synthesized [14], but only two of these currently are 
being used in clinical trials. The first, primarily used in 
Japan is a polyhedral borane anion, sodium 
borocaptate or BSH (Na2B12H11SH), and the second is 
a dihydroxyboryl derivative of phenylalanine, referred to 
as boronophenylalanine (BPA). The BPA has been 
used in clinical trials in the United States, Europe, 
Japan, Argentina and Taiwan. Following administration 
of either BPA or BSH by intravenous infusion, the 
tumor site is irradiated with neutrons, the source of 
which has been specially modified nuclear reactors. Up 
to 1994, low-energy (< 0.5 eV) thermal neutron beams 
were used in Japan [15], but since they have a limited 
depth of penetration in tissues, higher energy 
(>0.5eV<10 keV) epithermal neutron beams, which 
have a greater depth of penetration, have been used in 
clinical trials in the United States [16, 17], Europe [18, 
19], and Japan [20, 21]. Boron containing nano 
particles and boron carbide particles delivery agents 
has also been evaluated [22]. 
The BNCT is a highly selective type of radiotherapy 
that can target the tumor at the cellular level without 
causing radiation damage to the adjacent normal 
tissues. By BNCT doses up to 60–70 Gy can be 
delivered to the tumor cells in one or two applications 
compared to 6–7 weeks for conventional external beam 
photon irradiation.  
2.2. Cesium-137 
The half life of Caesium-137 (137Cs) is 30.1 years 
and disintegerates by beta (β-) emission to metastable 
Barium-137m (137mBa) (94.4% of the time), emitting an 
electron with energy of 512 keV. 137mBa releases a γ 
photon as it returns to its ground energy state, with 
energy of 662 keV. Fission yield of 137Cs is ~ 6% by 
fission reaction of various isotopes of thorium, uranium, 
and plutonium [23]. Generally 137Cs is produced by 
fissioning uranium-235 (235U) nuclei and then 
chemically separating the cesium from the irradiated 
nuclear fuel or targets. Separated 137Cs sold 
internationally is produced only by the Production 
Association Mayak (PA Mayak) in the Chelyabinsk 
region of Russia and sold through REVISS; a U.K.-
based company[24]. It is supplied as cesium chloride, a 
crystalline salt. Cesium-137 teletherapy units are 
designed for treatment of different source to skin 
distances (SSD) [25]. 
Radioactive sealed sources of 137Cs as CsCl are 
manufactured either as an insoluble powder, ceramic 
microspheres or a solid ceramic rod. The radioactive 
material is then doubly encapsulated in stainless steel, 
with each layer welded shut. 137Cs replaced radium-
226 (226Ra) for temporary interstitial / intracavity low 
dose rate brachytherapy due to its stable daughter 
product and improved radiation protection features. 
The 137Cs radioactive sealed source is widely used 
for the treatment of gynecological cancer [26]. Uses of 
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different strengths sources of 137Cs are essential to 
achieve the desired dose distribution. In modern 
remote afterloading devices iridium-192(192Ir) is 
preferred radionuclide. 
Low dose-rate (LDR) systems use multiple 
radioactive sources, together with inactive spacers to 
get typical dose rates of about 0.4–2 Gy/h. On the 
other hand, high dose-rate (HDR) devices use a single 
source of 192Ir, with a typical radioactivity of 10-20 Ci 
(370-740 GBq), delivering treatment dose rates 
exceeding 2 Gy/min. Oral tongue carcinoma is highly 
curable when treated with radiation therapy, especially 
via interstitial brachytherapy [27]. 
2.3. Chromium-51 
Chromium-51(51Cr) has a half-life of ~ 27.7 days, 
disintegerates by electron capture (EC) resulting in 
emission of γ photons with energy of 0.320 MeV 
(9.83%) [28]. The published literature shows that 2 
production methods for 51Cr are practiced. The first one 
is the direct neutron bombardment of enriched or 
natural 50Cr(n,γ)51Cr [29], while the second one is 
based on Szilard-Chalmers reaction using specially 
chosen chromium compounds [30, 31]. Sodium 
chromate (51Cr) is useful for determining red blood cell 
(RBC) volume or mass, studying RBC survival time (in 
conditions such as hemolytic anemia), and evaluating 
blood loss [32]. The suggested dose range in the 70 kg 
patient for determination of RBC volume or mass is 
0.37 - 1.11 MBq (10-30 µCi). For study of RBC survival 
time is 5.55 MBq (150 µCi) while evaluation of blood 
loss needs 7.40 MBq (200 µCi). This drug has not been 
found by Federal Drug Administration (FDA) to be safe 
and effective, and this labeling is not recommended by 
FDA of USA [33].  
2.4. Cobalt-60  
Cobalt-60 (60Co) has a half-life of 5.27 y. 60Co is 
produced in a reactor (Research or Power) by 
59Co(n,γ)60Co nuclear reaction. It undergoes β- decay 
emitting an electron and a neutrino and emits two γ 
rays with each decay; one at 1173 keV and one at 
1333 keV [34]. Cobalt-60 teletherapy devices are used 
to treat malignant tumors in human body. The 
teletherapy radiation source is kept at a distance from 
the patient and a beam of radiation is directed to the 
tumor. Teletherapy machines contain 37 to 550 TBq 
(1,000 to 15,000 Ci) and, at least in the United States 
virtually all (247 of 248) use cobalt-60 (one uses 
cesium-137) [35]. The Gamma Knife® competes with 
linear accelerator machines for the treatment of 
centimeter-sized brain tumors in areas of the brain 
where conventional surgery generally is not possible. 
There are approximately 200 Gamma Knife® devices 
worldwide, including at least 104 in the United States. 
Elekta, a Swiss/Swedish company is the sole 
manufacturer of the Gamma Knife®, while MDS 
Nordion is the main source for the small cobalt-60 
sealed sources. A Chinese company, Gamma Star, 
has begun to market a competing device and Elekta is 
now selling a new version of the Gamma Knife® with 
192Ir sources, instead of the 201 encapsulated 60Co 
sealed sources used in previous models [35]. Cobalt- 
60 teletherapy machines provide relatively high energy 
γ rays for therapy which are ideally suited for treatment 
of head and neck carcinomas and other superficially 
located tumors, such as breast cancers and soft tissue 
sarcomas of extremities. 60Co sources are not 
adequate for treatment of deep seated tumors and 
have the added disadvantage of decreasing output with 
decay of source and the need for source replacement 
within 5-7 years, due to 5.27 y half-life of 60Co. 
In 1962 Walstam [36] introduced the first concept of 
a remote afterloader equipped with 60Co. Since its 
introduction, 60Co has achieved tremendous success 
and has continued to evolve to support modern HDR 
brachytherapy needs. Cobalt-60 has been shown to be 
a good choice for treating gynecological, rectal, 
prostate, breast, esophagus, skin, and other body sites 
[37-41]. The treatment with 60Co leads to lower dose to 
organs at risk (OAR) than with 192Ir. Due to its higher 
mean energy of 1.25 MeV, less backscatter is 
produced and therefore, 60Co shows a more linear 
radial dose function than 192Ir with 0.37 MeV. Due to 
the long half-life of 60Co, the source can be used for up 
to 5 years which means that during the recommended 
working life of a single 60Co source, approximately 20 
source exchanges of 192Ir would have to be performed. 
Copper-64 
Copper-64(64Cu) has a half-life of 12.7 h. It 
disintegrates by three processes; positron emission, 
electron capture, and β- decays. The decay 
characteristics; β+ 653 keV (17.8 %); β- 579 keV (38.4 
%) allow the positron emission tomography (PET) 
imaging as well as targeted radiotherapy of cancer. 
The nuclear reactor production routes result in either 
low specific activity by 63Cu(n,γ)64Cu or high specific 
activity by 64Zn(n,p)64Cu reactions [42, 43]. Large 
quantities of 64Cu with high specific activity are usually 
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produced using a cyclotron via 64Ni(p,n)64Cu nuclear 
reaction [44, 45]. 
It was supposed that Wilson Disease patient may 
have increased uptake of Cu in brain tissue and 
pathologic analysis of the brain tissue may show gliosis 
and neuronal loss in association with increased Cu 
deposition. 64CuCl2 PET may serve as a 
straightforward, noninvasive and quite simple tool for 
the diagnosis of Wilson Disease [46]. Currently 
nanodevices/nanoparticles [47] have been used in 
biomedical field investigating new and improved 
diagnosis and therapy agents and with sufficient 
development, the 64Cu is likely to become an important 
radionuclide in nuclear medicine in coming years. 
2.5. Fluorine-18 
Fluorine-18 (18F) has a half-life of 109.7 min and 
decays by positron (β+) emission. 97 % of the decay 
results in emission of a β+ with a maximum energy of 
0.633 MeV and 3% of the decay results in EC with 
subsequent emission of characteristic X-rays of 
oxygen. The principal photons useful for diagnostic 
imaging (positron emission tomography-PET) are the 
0.511 MeV γ photons, resulting from the interaction of 
the emitted β+ with an electron.18F atom decays to 
stable 18O-oxygen. There are many charged particle 
reactions that are used to produce 18F in accelerator 
[48]. The widely used method consists of irradiating a 
small volume of enriched H218O in a metal target with 
protons of energies from near threshold, approximately 
3-20 MeV [49-51]. 
According to United States Pharmacopoeia (USP), 
Sodium Fluoride (18F) injection is used for diagnostic 
positron emission tomography (PET) imaging of bone 
to define areas of altered osteogenic activity. With 
clinical experience in ~ 100 children, weight based 
doses (2.1 MBq/kg) ranging from 19 MBq to 148 MBq 
(0.5 mCi to 4 mCi) were used. Dose for adults are 300 
MBq/mL to 450 MBq/mL (8 mCi/mL to 12 mCi/mL) as 
an intravenous injection. Fluoride (18F) ion normally 
deposits in the skeleton in an even fashion, with 
greater accumulation in the axial skeleton (e.g. 
vertebrae and pelvis) than in the appendicular skeleton 
and greater accumulation in the bones around joints 
than in the shafts of long bones [52-55]. 
2.6. Iodine-123 
Iodine-123 (123I) has a half-life of 13 h and primarily 
a gamma-emitter. Iodine-123 decays by EC to emit a 
high-speed internal conversion electron, which is not a 
β- particle, but this could little cellular damage due to 
the nuclide's short half-life and the relatively small 
fraction of such disintegration events. 123I also 
disintegrates decays to emit a 0.159 MeV γ ray, which 
is quite suitable for gamma camera imaging. The 123I is 
widely used for thyroid imaging to evaluate the 
anatomic and physiologic function of the thyroid 
disorders [56, 57]. 
The 123I is mainly produced by two routes. The first 
one is the direct route and the second is through the 
xenon-123 (123Xe) precursor. The advantage of 123Xe 
production route is that the xenon can be isolated from 
the irradiated target material and allowed to decay in 
isolation, which gives the 123I with almost negligible 
contamination from other radioiodine. The most 
common reaction used for the production of 123I has 
been the 124Te(p, 2n) 123I reaction employing highly 
enriched 124Te [58].  
2.7. Iodine-124 
Iodine-124 (124I) is a proton-rich isotope of iodine 
with a half-life of 4.18 days. Its modes of decay are 
about 75% electron capture and 25% positron 
emission. The use of 124I is becoming more 
widespread. Iodine-124 has potential as both a 
diagnostic and a therapeutic radionuclide. The main 
use of iodine-124 is to directly image the thyroid using 
positron emission tomography [59]. Iodine-124 can also 
be used as a PET radiotracer with a usefully longer 
half-life compared with fluorine-18. In this use, the 
nuclide is chemically bonded to a pharmaceutical to 
form a positron-emitting radiopharmaceutical, and 
injected into the body, where again it is imaged by PET 
scan (60-62). 
The best nuclear reaction for the production of 124I is 
the 124Te(p, n)124I reaction on enriched 124Te [63].  
2.8. Iodine-125 
Iodine-125 (125I) has a physical half-life of ~60d, and 
disintegrates by 27-32 keV Te X rays and 35 keV γ 
ray). It is a radionuclide of iodine, which has major uses 
in biological assays (e.g., radioimmunoassay-RIA) and 
as a radioactive sealed source in radiation therapy as 
brachytherapy (prostate and brain tumors treatment). 
The neutron irradiation of 124Xe by n,γ reaction 
produces 125I in a nuclear reactor. The separation of Xe 
and I is carried out by dry distillation technique [64]. 
Due to better radiation penetration and shorter half-life 
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123I is preferred over 125I for thyroid imaging. In addition 
to its use in biological assays [65], 125I is generally used 
by radio-oncologists as brachytherapy to treat cancer 
at sites other than the thyroid, such prostate cancer 
and brain tumors [66, 67]. When the radioactive sealed 
source of 125I is used in therapy, it is encapsulated in 
titanium (Ti) seeds and implanted in the area of the 
tumor, where it remains. The low energy of the γ 
spectrum of 125I limits radiation damage to tissues far 
from the implanted seeds. 
Iodine-125 was finally introduced in interstitial 
cancer therapy, such as prostate, lung cancer and 
lymph nodes in 1965 [68]. Since 1979 it has been 
applied for treatment of brain tumours. Even though the 
physical and biological characteristics make 125I 
implants quite attractive for minimal invasive treatment 
damages, the place for stereotactic brachytherapy is 
still poorly defined [69].  
2.9. Iodine-131 
Iodine-131 (131I) has a half-life of 8.025 days and 
disintegrates with β- (100%) emission to stable131Xe 
(99%) and to 11.8 d 131mXe (1%), with an average β- 
particle energy of 182 keV. The decay of 131I is followed 
by emission of high intensity gamma ray at 0.365 MeV 
(81.5%). Other γ ray include 0.637 MeV (7.16%), 0.284 
MeV (6.12%), 0.080 MeV (2.62%), and several weaker 
γ rays [70].  
Saul Hertz in 1941 reported the therapeutic use of 
131I to treat hyperthyroidism from Grave's disease [71]. 
The usual sodium iodide-131I dose range is 148 to 370 
MBq (4 to 10 mCi) for the treatment of hyperthyroidism, 
[72]. Higher doses may be effective for the treatment of 
toxic nodular goiter and other peculiar situations. For 
thyroid carcinoma, the usual sodium iodide-131I solution 
therapeutic dose is 3700 to 5550 MBq (100 to 150 mCi) 
[73].  
The post-operative residual thyroid tissue ablation is 
performed by a usual dose of 1850 MBq (50 mCi) [74].  
Sodium iodide-131I solution given orally is rapidly 
absorbed and distributed within the extracellular fluid of 
the body. The iodide is accumulated in the thyroid via 
the sodium/iodide symporter, and subsequently 
oxidized to iodine. The β- particles emitted by 131I 
destroy the thyroidal tissue. The therapeutic effects of 
131I are a result of the ionizing radiation absorbed by 
the thyroidal tissue. Approximately 90% of local 
irradiation dose from 131I is the result of β- radiation and 
10% is the result of γ radiation.  
Iodine-131 is generally produced in a reactor by the 
neutron irradiation of tellurium according to the nuclear 
reaction 130Te(n, γ) 131Te β- 131I. The iodine is 
separated from the TeO2 target material by dry 
distillation technique above 750oC and Te metal by wet 
distillation methodology [75, 76] absorbed in dilute 
sodium hydroxide solution.131I is also a fission product 
with a yield of 2.878% from 235U, An elaborate 
technology is required for separation of 131I from fission 
products [77]. 
2.10. Iridium-192 
Iridium-192 (192Ir) is produced by (n,γ) reaction on 
191Ir in a nuclear reactor. 192Ir has a half-life of 74.2 
days and disintegrates to stable platinum-192 (192Pt) 
and emits β- particles of maximum energy of 672 keV 
(46%) and γ rays of energies of 604, 468 and 308 keV. 
The iridium (>99.9 % purity) target is irradiated in a 
high flux reactor, providing more than 2x 1014 n.cm-
2.sec-1 neutron flux density, because specific activity of 
the irradiated target should be more than 16.8-18.5 
TBq/g (450-500 Ci/g). Activity of the 192Ir HDR 
assembly should be more than 370 GBq (10 Ci) for 
effective therapy [78]. Low dose rate 192Ir is 
manufactured in lengths of wire 10-14 cm long and 0.3 
mm thick, which can be cut into the desired length for 
LDR applications. The wires are flexible and inert to 
body fluid. 
The HDR 192Ir sources are composed of 
platinum/iridium alloy having a 3.5 mm long, 0.6 mm 
diameter with a high specific activity of 192Ir. It is coated 
in 1 mm of platinum, which attenuates any electrons 
emitted through decay. This capsule is welded to the 
end of a wire that allows it to be retracted and deployed 
from within a High Dose Rate remote afterloading 
device. Iridium-192 HDR brachytherapy is a suitable 
alternative in the treatment of localized prostate cancer 
who are not eligible for radical prostatectomy [79]. 
Traditionally, High Dose Rate after loaders have 
been based on Ir-192. The high specific activity of 
iridium allowed very small sources to be used 
interstitially despite its half-life period. Typically a 
source exchange is required each 3-4 months to keep 
the treatment times within the limits required by clinical 
practice and also because a maximum number of 
transfers is recommended by the manufacturer. The 
Cobalt-60 manufacturer claims important economic 
advantages because of the larger half-life period and 
the improved technology which allow for less source 
exchange frequency [80]. The Brachytherapy treatment 
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may improve the control of local tumor and prolong the 
survival of patient, when used in deep malignant brain 
gliomas, by temporary implanted high doses of 192Ir 
radioactive sealed sources [81]. 
Catheter-based brachytherapy using 192Ir seeds has 
shown valuable reduction in the rate of restenosis in 
patients with coronary in-stent restenosis [82].  
Women with locally advanced or recurrent 
gynecological malignancies treated with the remote 
afterloader LDR MUPIT applicator can expect 
reasonable rates of local control that are not operator-
dependent [83]. 
According to published reports, fractionated HDR 
brachytherapy represent one option for the primary 
treatment of cervical carcinoma [84]. 
2.11. Krypton-81m 
Krypton-81m (81mKr) has a half-life of 13 sec and is 
a gas produced from the decay of rubidium-81 (81Rb) 
having a half-life of 4.6 h [85]. The 81mKr gas has an 
ideal γ energy of 193 keV suitable for gamma imaging. 
Rubidium-81 decays by positron emission and electron 
capture. The main reaction for the production of 81Rb is 
the proton reaction of natural krypton [86]. 81Rb solution 
having certain concentration is fixed on to AG50W-X8 
cation exchange column. The cation resin has a high 
affinity for Rb, while the daughter 81mKr is eluted by 
sterile air or sterile water. In the case of water, an 
adjustment is made with a sodium chloride solution of 
appropriate concentration [87]. 81Rb/81mkr generators 
are used either in gaseous form for ventilation imaging 
or in solution for lung perfusion imaging.  
The short half-life of 13 sec implies that inhaled 
81mKr disappears from the alveolar space at a much 
faster rate by decay than by exhalation. When a patient 
is breathing air with 81mKr at a normal respiratory rate, 
the regional alveolar 81mKr concentration is at steady 
state, closely proportional to regional ventilation. 
Deviation from proportionality occurs in lung 
compartments with very high or low regional ventilation 
in relation to resident alveolar volume [88]. This 
deviation occurs in children with a high ventilatory rate 
and a high ventilation/volume ratio [89]. During steady-
state 81mKr ventilation, multiple planar imaging or 
SPECT acquisition can be performed. Very recently, 
Ventilation/Perfusion SPECT in combination with low-
dose CT has been reported [90]. 81mKr has an 
advantage that ventilation and perfusion can be imaged 
simultaneously as 81mKr has higher γ energy of 193 
keV than technetium-99m (99mTc) of140 keV, which is 
used as a perfusion marker [91, 92]. As 81Rb has a 
short half-life of only 4.6 h, the 81Rb/81mkr generator can 
be used for 1 day only. Very low radiation exposure to 
patients makes 81mKr an alternative to radioactive 
aerosols and particularly advantageous for use in 
young children [88]. 
2.12. Nitrogen-13  
The physical half-life of Nitogen-13 (13N) is 9.96 
min, hence application is limited and requires an on-
site cyclotron production technology. Nitrogen-13 
decays by only positron emission (100%) to stable 
carbon-11 (13C). The end point energy of the β+ is 1.19 
MeV. There are several charged particle reactions 
leading to the production of 13N [93]. The widely used 
production route is the16O(p, α)13N reaction on water 
using 16.5 MeV protons [94-96]. Over the past 3 
decades 13N labeled ammonia has been used for most 
of the scientific investigations in cardiac PET imaging. 
Intravenous injection, typically 10-20 mCi (370–740 
MBq) as a bolus is useful in these studies [97, 98]. Two 
methods are commonly used for 13N-ammonia 
synthesis. In the first method, the 13N-labeled 
nitrates/nitrites formed by proton irradiation of water are 
reduced by either titanium (III) chloride, titanium (III) 
hydroxide, or Devarda’s alloy (an alloy of aluminum 
44–46%, copper 49–51%, and zinc 4–6%) in alkaline 
medium [99]. After distillation, trapping, and sterile 
filtration, 13N-ammonia is available for injection. In the 
second method, oxidation of 13N to 13N-nitrates/nitrites 
is prevented by the addition of ethanol as a scavenger 
to the target content [100]. The target content is passed 
through a small cation-exchange column to trap 13N-
ammonium ions, and 13N-ammonia is then eluted with 
physiological saline and filtered through bacteria filter 
before its use.  
2.13. Oxygen-15  
Oxygen-15 (15O) is the longest lived (Half-life: 122 
s.) of the β+ emitting radionuclide (99.9% β+ emission) 
of oxygen. The end point energy of the β+ is 1.72 MeV. 
Oxygen-15 disintegrates to stable 15N. Various charged 
particle reactions leading to the production of 15O have 
been described [101]. Oxygen-15 is commonly 
produced using a deuteron particle reaction on N gas 
or a proton particle reaction on enriched 15N gas. [15O]-
water has also been produced by bombarding natural 
water using the 16O(p, pn)15O route, with a final 
purification on an ion exchange column [102]. Oxygen-
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15 water is a freely diffusible agent with very high 
myocardial extraction across a wide range of 
myocardial blood flows [103]. The degree of extraction 
is independent of flow and is not affected by the 
metabolic state of the myocardium. Since oxygen is a 
freely diffusible tracer, but imaging is challenging due 
to its high concentration in the blood pool. 
2.14. Palladium-103 
Palladium-103 (103Pd) has a 17-day half-life and X-
ray photon emission at the main energies of 20.07 keV 
(19.83%), 20.22 keV (37.55%) and 22.71 keV (37.55%) 
[104].103Pd is commonly produced by cyclotron 
irradiation of rhodium targets with accelerated protons. 
This approach allows production of carrier-free 103Pd 
having near theoretical value of specific activity of 
75000 Ci/g (~2.8 106 GBq/g) [105].  
An alternative approach to 103Pd production is 
reactor irradiation of isotopically enriched 102Pd. 
The low natural isotopic abundance of 102Pd 
(1,02%) requires the use of moderate to highly 
enriched 102Pd target material of no less than 50%. 
Moreover, the low cross-section of 102Pd(n,γ)103Pd 
nuclear reaction (thermal cross-section is 3.4 barn, 
resonance integral 10 barn) requires also the use of 
highflux nuclear reactors, like the HFIR (ORNL, Oak-
Ridge, USA) or SM (RIAR, Dimitrovgrad, Russia), to 
produce high-specific activity 103Pd [105]. The 
effectiveness of 103Pd brachytherapy in Stage T1 and 
T2 adenocarcinoma of the prostate has been rvaluated 
[106]. A review of 123 early stage T1c and T2 prostate 
cancer patients implanted at Yale University with125I 
(82 patients) or 103Pd (41 patients) reveals a 
significantly lower overall complication rate with 103Pd 
(0%) versus 125I (13%) [107]. 
2.15. Phosphorus-32 
The half-life of Phosphorus-32 (32P) is 14.29 days 
and it decays solely with the emission of β- particles, 
with a mean energy of 0.695 MeV (Emax =1.71 MeV), 
to stable sulfur. In a reactor 32P is produced by 31P(n,γ) 
32P and 32S(n,p)32P reactions. No carrier added 32P is 
produced by irradiation of sublimed sulfur targets filled 
in aluminum capsules in a reactor. Dry distillation 
technique is used for separation of sulfur from 32P 
[108].  
Sodium phosphate (32P) solution must be injected 
carefully and after intravenous injection a saline flush 
must be followed to prevent venous thrombophlebitis. 
An inadvertently administered subcutaneous injection 
of Sodium phosphate (32P) may lead to radio-necrosis 
of the surrounding tissues. 
For the palliative treatment of primary proliferative 
polycythemia and / or essential thrombocythemia, the 
usual initial intravenous dose is 100 MBq (2.7 
mCi)/body surface area (m2). The use of maximum 
radioactivity 185 MBq (5 mCi) is recommended, but 
initial activities of 74-260 MBq (2-7 mCi) have been 
applied. When hormone treatment, chemotherapy, 
radiotherapy or any other therapy have failed, the bone 
pain may be treated by doses of 370-555 MBq (10-15 
mCi), administered at 3-4 month intervals, Reduction in 
bone pain may take a few weeks and it may be 
associated with increased treatment compliance and 
reduced used of analgesics. Small intravenous doses 
of sodium phosphate (32P) generally did not cause 
pharmacodynamic effects. Phosphorus is nearly1% of 
total body weight and affects the functioning of bones, 
red blood cells and the nervous system. The selective 
accumulation of 32P by the hematological tissues will 
exert a continuous exposure to the dividing cells which 
will have a significantly detrimental effect on their 
survival. The accumulation of phosphate by different 
tissues is dependent on the existing amount of tissue 
phosphate, the amount of new tissue matter and the 
vascularization of the tissue etc, [109]. The treatment of 
polycythemia rubra vera by using sodium phosphate 
(32P) was first reported in 1955 [110]. 
Chromic phosphate (32P) is indicated by intracavity 
instillation for the treatment of peritoneal and pleural 
effusions caused by metastatic disease. In the 
presence of large tumor masses, other forms of 
treatment may be indicated; however, chromic 
phosphate-32P may control the effusion when other 
treatment has failed [111, 112] Bloody effusions may 
reduce the effectiveness of treatment. Chromic 
phosphate is indicated by interstitial injection for the 
treatment of cancer, such as cancer of the ovary (early-
stage) and of the prostate [113].  
Colloidal chromic phosphate (32P) administered into 
a body cavity is phagocytized by free macrophages 
and fixed to the lining of the cavity wall, thus providing 
local irradiation to the affected area [114]. Usual adult 
and adolescent dose for Malignant effusions are; 
Intraperitoneal instillation, 370 to 740 MBq (10 to 20 
mCi) and Intrapleural instillation, 222 to 444 MBq (6 to 
12 mCi). For treatment of Carcinoma, the Interstitial 
injection, 3.7 to 18.5 MBq (0.1 to 0.5 mCi) per gram of 
estimated tumor weight [115]. The FDA has approved 
Inorganics in Nuclear Medicine International Journal of Nuclear Medicine Research, 2016, Vol. 3, No. 1    27 
three brachytherapy delivery systems for in-stent 
restenosis: Cordis Checkmate System™ (iridium-192 
seeds for γ radiation), Novoste Beta-Cath System™ 
(strontium-90 for β- radiation), and the Galileo 
Intravascular Radiotherapy System™ (phosphorus-32 
wire for β- radiation). These systems are intended for 
use in intracoronary brachytherapy only and all have 
similar labeling that limits the approved use of the 
devices to treatment of in-stent restenosis. No devices 
have been approved or recommended for approval for 
primary prevention of in-stent restenosis. There are 
currently no FDA-approved devices for brachytherapy 
of noncoronary arteries [116]. Lawrence and Tobias' 
were the first to use radioactive phosphorus (32P) on 
neoplastic tissues. Later, 32P was used for palliation of 
pain from bone metastases [117, 118]. 
2.16. Radium  
Radium (Ra) has thirty three known nuclides, with 
mass numbers from 202 to 234 and all are radioactive 
[119]. Four radionuclides occur naturally in the decay 
chains of thorium-232, uranium-235, and uranium-238. 
These are 223Ra (half-life=11.4 days), 224Ra (half-
life=3.64 days), 226Ra (half-life=1600 years), and 228Ra 
(half-life=5.75 years). Radium-226 is the most long 
lived radionuclide of Ra, which has a half-life of 1600 
years and disintegrates into radon gas. In nature, 
radium is found in uranium and thorium ores in trace 
amounts as small as a seventh of a gram per ton of 
uraninite. In 1898 Marie Curie and Pieree Curie 
discovered Ra in the form of radium chloride [120]. 
Natural radium mostly comprises 226Ra and emits 
mostly α particles, but other steps in its decay chain 
(the uranium or radium series) emit α or β- particles, 
accompanied by γ rays [121]. The biological effects of 
radium were known to some extent from its discovery. 
Antoine Becquerel became ulcerated by carrying a 
small ampoule of radium in his waistcoat pocket for 6 
hours. Pierre Curie observed skin lesion when attached 
a tube filled with radium to his arm for 10 hours. These 
observations raised the question that if Ra can destroy 
healthy tissue, could it also destroy cancerous tissue 
[122]? 
Kelly, physicians of Johns Hopkins Hospital, a major 
pioneer used Ra for the treatment of cancer [123]. In 
1906, Kelly treated his own aunt but she died shortly 
after surgery [124]. He used excessive amounts of Ra 
to treat various tumors and cancers, resulting in the 
deaths of some of his patients due to high doses of Ra 
[124]. Kelly inserted a Ra capsule near the affected 
area then sewed the radium "points" directly to the 
tumor [125]. Similar technique was used to treat 
Henrietta Lacks, the host of the original HeLa cells, for 
cervical cancer [126]. Radium chloride or bromide was 
commonly used to produce radon gas which was used 
as a cancer treatment and several of such radon 
sources were used in Canada during the 1920s and 
1930’s [127, 128].  
Several treatments that were performed in the early 
1900s are not used anymore because of the harmful 
effects like, anaemia, cancer, and genetic mutations 
caused by RaBr exposure [129]. 
Now-a-days 223Ra and 224Ra are used as 
therapeutic agents. Radium-223 dichloride is an α 
emitter used in the treatment of patients with prostate 
cancer that is resistant to medical or surgical 
treatments. This type of cancer lower testosterone and 
has spread to only bones with symptoms. Radium-223 
dichloride is given intravenously slowly, over about 1 
minute. The drug mimics calcium (Ca) and forms 
complexes with the bone mineral at sites of bone 
metastatses. It then emits α particles, causing the DNA 
destruction in nearby cells, resulting death of cancer 
cells in the bone. Radium-223 acts as an internal 
radiotherapy treatment agent. It is a mildly radioactive 
and commercially sold by the name of Alpharadin and 
now has the brand name Xofigo [130]. 
Although 223Ra is generated in trace amounts by the 
disintegration of 235U, it is generally made artificially by 
irradiating natural 226Ra to neutrons to produce 227Ra, 
which decays with a 42 min half-life to actinium-
227(227Ac). Actinium-227 has a half-life 21.8 years and 
decays via 227Th (half-life 18.7 days) to 223Ra. Hence 
the decay path makes a generator system of 
227Ac/223Ra[131]. 
224Ra has a half-life of 3.2 days and has been used 
for many decades to treat ankylosing spondylitits [132]. 
Recently in Germany, it has been reintroduced and 
reapproved for ankylosing spondylitits [132]. In the 
case of 224Ra, long term follow up of patients receiving 
moderate levels revealed no significant difference in 
overall cancer incidence or life expectancy compared 
to a control population [133]. Radium-224 is a natural 
daughter product in the decay chain of natural 232Th to 
228Th [134]. 
Brachytherapy can be traced historically with 
applications of 226Ra sources, which involved exposure 
of the surrounding tissue. Treatment of oral tongue 
carcinoma has been quite successful when treated with 
radiation therapy particularly by interstitial 
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brachytherapy [135]. To make comparison simple, the 
patients treated by one of the three major sources, 
226Ra, 192Ir and MS-HDR (192Ir) were examined. 
2.17. Rhenium-186 
Rhenium-186 (186Re) has a physical half-life of 3.7 
days and it emits a β- particle with a a mean energy of 
349 keV, maximum energy of 1070 keV, and an 
average soft tissue range of 1.1 mm. 186Re also emits 
9% abundant γ emission of 137 keV. In a nuclear 
reactor low specific activity 186Re can be made 
available from neutron irradiation of 185Re [136]. Proton 
or deutron bombardment of enriched tungsten targets 
can produce high specific activity 186Re [137-139]. 
The use of Re-186-labelled sulfur colloid particles 
for therapy of rheumatoid arthritis of the synovial joints 
is quite successful. 186Re sulpfur colloid is suitable for 
hip, shoulder, elbow, wrist, ankle and subtalar 
joints.The administered activity and the injected volume 
of 186Re sulfide colloid depends on the volume of the 
joint to be treated [140]. The maximum activity of 186Re 
at a single session should be ~ 370 MBq (10 mCi). The 
use of Re-186-liquid-filled balloons for restenosis 
therapy has also been evaluated [141]. Rhenium-186-
labelled particles are sold commercially in European 
countries and the supplier recommends 186Re sulfide 
colloid, for radiosynovectomy of medium size joints 
[142]. 
2.18. Rhenium-188 
Rhenium-188 (188Re) has a half-life of 16.9 h and 
emits a β- particle with a maximum energy of 2.12 MeV, 
useful for therapeutic applications. It also emits a 155 
keV gamma photon (15%) for gamma camera imaging. 
Rhenium-188 can be produced with high specific 
activity by neutron irradiation of enriched187Re in a 
nuclear reactor [143]. However carrier-free 188Re as 
perrhenate is usually obtained from the 188W/188Re 
generator in the clinic at a certain time. Elution of 
generator after every 24 hours provides ~60% yields of 
188Re. Alumina based column chromatography 
generators for 188W/188Re system is generally used and 
commercially available. Tungsten-188 (188W; T1/2: 69 
d), is reactor-produced by double neutron capture on 
tungsten-186, which is the parent isotope of 188Re 
[144]. 
A simple method for preparation of Re-188-labelled 
sulfur colloid is reported [145], which provides a tight 
particle size range of 86% = 5 µm. The most activity is 
retained in the liver via intravenous or hepatic artery 
injection. Rhenium-188 sulfide preparations have 
shown usefulness when injected in tumors and used in 
radiosynovectomy [146, 147]. 188Re sulfide colloid is 
commercially available for radiosynovectomy of large 
size joints [142].  
Re-188-labelled agents for the use of 188Re liquid-
filled angioplasty balloons inflated at low pressure 
following coronary angioplasty for the inhibition of 
coronary restenosis by high dose delivery have been 
evaluated [148, 149]. Angioplasty balloons are filled at 
low pressure (2-3 atmospheres of inflation pressure) 
with a solution of 188Re-perrhenate or Re-lSS-MAG3 
following high pressure angioplasty to deliver a dose of 
2500-3000 rad at 0.5 mm of depth. Patient studies 
have been performed at several Institutions in the USA, 
Europe and Australia.  
For vascular radiation therapy or for other 
applications which require a 188Re liquid-filled balloons, 
the pooled experience obtained thus far from several 
collaborative clinical sites, a total volume of 1.5-2 mL of 
the rhenium-188 solution with a specific volume (up to 
250 mCi/mL) which is required for use in the 
Catheterization Laboratory. Although the actual balloon 
volume will probably not be greater than 0.15 - 0.20 mL 
even for large coronary vessels, the extra volume is 
required for filling the lines, valves, etc., and to have 
sufficient back pressure in the inflation syringe [150]. 
2.19. Rubidium-82  
The half-life of strontium-82 (82Sr) is parent nuclide 
with 25 d half-life, while the daughter rubidium-82 
(82Rb) has a half-life of 1.25 min [151]. Strontium-82 
decays via EC, while the daughter, 82Rb decays 95.5% 
by β+ emission, resulting in the production of 
annihilation radiation of two 511 keV γ rays; and 4.5% 
by EC, resulting in the emission of “prompt” γ rays of 
predominantly 0.777 MeV. Both decay modes of 82Rb 
lead to the formation of stable 82Kr nuclide. The only 
useful charged particle reaction for the production of 
82Sr using protons is the high energy reaction of 
metallic rubidium target material 85Rb(p, 4n)82Sr [152]. 
The 82Sr can also be produced in an accelerator by 
proton spallation of molybdenum (Mo) with a high-
energy 800 MeV proton accelerator, followed by 
chemical purification technique [153]. Cardiogen-82 
generator system contains accelerator-produced 82Sr 
fixed on stannic oxide column properly shielded by lead 
(Pb) provides nonpyrogenic solutions of 82Rb chloride 
for injection purposes [154]. The 82Rb is eluted with 25-
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50 mL physiological saline (0.9% NaCl) by a computer-
controlled elution pump, connected by Intravenous 
tubing to the patient. The 82Sr/82Rb generator is fully 
replenished every 10 minutes and 90% of available 
activity of 82Rb can be eluted within 5 minutes since the 
last elution, making serial imaging every 5 minutes. 
Rubidium-82 has proven an efficient heart imaging 
agent for routine clinical usage [155,156]. The 
recommended adult single dose of 82Rb-chloride 
injection is 1480 MBq (40 mCi) with a range of 1110-
2220 MBq (30-60 mCi). Rubidium is analogous to 
potassium ion (K+) in its biochemical behavior and is 
rapidly extracted by the myocardium proportional to the 
blood flow. Rubidium cation participates in the sodium-
potassium (Na+/K+) ion exchange pumps that are 
present in cell membranes. The intracellular uptake of 
82Rb requires maintenance of ionic gradient across cell 
membranes. Rubidiumb-82 radioactivity is accumulated 
in viable myocardium reflecting intracellular retention, 
while the radiotracer is cleared rapidly from necrotic or 
infarcted tissue [154].  
2.20. Strontium-89 
Strontium-89 (89Sr) has a half-life of 50.5 d and 
decays by β- emission. The maximum β- energy of 89Sr 
is 1.463 MeV (100%). The maximum energy of ß- 
particles capable of penetrating in tissue is 
approximately 8 mm. High specific activity and no-
carrier-added 89Sr can be produced by irradiating the 
natural yttrium in the fast neutron flux of a reactor via 
89Y(n,p)89Sr reaction. Low specific activity 89Sr can also 
be produced via 88Sr(n,γ)89Sr reaction in a reactor 
[157]. Following intravenous injection of 89SrCl2 behave 
like their calcium analogs, clearing rapidly from the 
blood and selectively localizing in bone mineral. 89SrCl2 
is retained in metastatic bone lesions much longer than 
in normal bone, where turnover is about 14 days. In 
patients with extensive skeletal metastases, more than 
50% injected radioactivity is retained in the bones. 
Uptake of Sr by bone occurs preferentially in sites of 
active osteogenesis; thus primary bone tumors and 
areas of metastatic involvement (blastic lesions) can 
accumulate significantly greater concentrations of Sr 
than surrounding normal bone. 89Sr is commercially 
available as a pharmaceutical brand name Metastron™ 
and is used as a bone pain palliation agent [158]. The 
recommended dose of 89SrCl2 is 148 MBq/4 mCi, 
administered by slow intravenous injection in1-2 
minutes. A dose of 1.5 - 2.2 MBq/kg, (40-60 µCi/kg) 
body weight may also be employed. 
2.21. Strontium-90 
Strontium-90 (90Sr) is a long lived radionuclide and 
has a half life of 28.8 years. It decays by β- emission 
with a maximum energy 546 keV to 90Y. Yttrium-90 
(90Y) has a short half life of 64 hours with a β- emission 
of 2.24 MeV. Ytrrium-90 exists in a secular equilibrium 
with 90Sr and is the main source of electrons for 
therapeutic applications. Yttrium-90 decays to stable 
90Zr. 90Sr is a fission product arising from the fission of 
235U, 238U or other heavy nuclei. Various extraction 
techniques for 90Sr from fission products have been 
described [159]. After 1 year of decay of burnt fuel 
rods, 90Sr represents 3.7% by mass of the total fission 
product inventory. Typically, 90Sr is combined with 
fluorine or chlorine to produce strontium fluoride 
(90SrF2) or strontium chloride (90SrCl2), respectively. 
Strontium-90 is a bone seeking element, similar to 
calcium. After entering the organism, approximately 
70–80% of the 90Sr gets excreted. Only 1% activity 
remains in blood and soft tissues, while all remaining 
strontium-90 is deposited in bones and bone marrow 
[160]. 90Sr radioactive sealed sources are prepared as 
a plaque - usually a silver disc coated in 90Sr. The disc 
is placed in a cavity within a Pb larger disc, and a very 
thin metal 'window' covers its external surface. 
Strontium-90 can also be used for endovascular 
brachytherapy, but typical use is in ophthalmic 
applicators for the treatment of pterygium [161, 162].  
The safety and efficacy of strontium (Sr90) beta 
radiotherapy as adjuvant treatment for conjunctival 
melanoma has been reported [163].  
2.22. Technetium-99m 
Technetium -99m (99mTc) has a half –life of 6 h and 
only emits 140 keV gamma ray, which is quite suitable 
for gamma cameras imaging. It is currently the most 
widely used radionuclide in diagnostic nuclear 
medicine. For the last 5 decades, it has dominated over 
all other nuclides used in nuclear medicine. 99mTc is the 
daughter product of 99Mo (T1/2 = 67 h) which can be 
obtained with low specific radioactivity either by 
irradiation of natural 98Mo (usually as MoO3) with 
thermal neutrons in a nuclear reactor [164] or with high 
specific activity from fission of 235U, also in a nuclear 
reactor [165]. The majority of the world’s supply of 
99mTc is derived from 99Mo/99mTc generators in which 
fission-produced 99Mo is adsorbed to a small alumina 
column. These generators are can be eluted with small 
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volumes of physiological saline to yield highly 
concentrated solutions of very pure 99mTc [166]. Other 
separation techniques like, solvent extraction, 
sublimation, gel technology etc, were employed for 
isolation of 99mTc from low specific activity 99Mo. 
2.22.1. Technegas 
Technegas is an ultra-fine suspension of carbon 
micro-particles labeled with 99mTc. A specially designed 
device called Technegas generator is employed for 
generation of technegas. In the generator a solution of 
sodium pertechnetate (Na99mTcO4) is introduced into a 
crucible and evaporated till dryness. In an inert 
atmosphere of argon gas technegas is generated by 
heating crucible to 2550 °C. The Technegas particles 
are hexagonal platelets of metallic 99mTc closely 
encapsulated with a thin layer of graphite. The size 
distribution of technegas particles being around 30-60 
nm with 80% of the particles being <100 nm. 
Technegas should be administered to the patient within 
10 minutes of its preparation [167]. Once technegas 
inhaled by the patient the gamma camera is used for 
imaging in the ventilation part of a Ventilation/Perfusion 
SPECT scan. Technegas penetrates to the sub-
segmental areas of the lung and is trapped by 
surfactant in the alveolar walls. Lung Scintigraphy has 
a superior sensitivity combined with adequate 
specificity and low rate of non-diagnostic tests. The low 
radiation dose, the possibility to quantify the degree of 
embolism and to use the test for follow-up of treatment 
of pulmonary embolism and its feasibility in very sick 
patients, contributes to the priority of lung scintigraphy 
over Computed Tomographic Pulmonary Angiography 
[168, 169].  
2.22.2. Technetium-99m Labelled Colloidal Particles 
Technetium-99m labelled colloidal particles, such as 
99mTc-antimony trisulphide colloid, 99mTc-sulphur 
colloid, 99mTc-rhenium sulphide nanocolloid and 99mTc-
tin colloid have been used for lymphoscintigraphy 
and/or sentinel lymph node (SLN) detection purposes. 
Technetium-99m labelled colloids slow elimination 
rates from the injection site and the uptake of 
radioactivity by lymph nodes is dependent on both 
particle size and the functional state of the 
reticuloendothelial system.  
Technetium-99m-antimony trisulphide colloid 
prepared by slowly adding a solution of potassium 
antimonyl tartrate to a hot saturated aqueous hydrogen 
sulphide solution has a particle size of 3–30 nm [170, 
171]. 99mTc-antimony trisulphide colloid provides 
satisfactory lymph node scans [170-172], but several 
adverse reactions requiring medical treatment have 
been reported [173]. 99mTc-sulphur colloid (99mTc-SC) 
produced by the reaction of thiosulphate with acid is 
unsatisfactory for lymphoscintigraphy because of the 
relatively large particle size and range (100–1000 nm), 
thus, 99mTc-SC produced by is filtered through a 0.1–
0.2 µm filter to obtain particles of smaller and even 
sizes, commonly used in clinical studies [174]. 99mTc-
sulphur colloid produced by passing hydrogen sulphide 
gas through an acidic pertechnetate solution, produces 
particle sizes of less than 100 nm, and the product 
provides satisfactory lymph node scans [175, 176]. 
Technetium-99m (99mTc) rhenium sulphide 
nanocolloid is used for lymphoscintigraphy for the 
purpose of visualising the regional lymphatic system. It 
can be used for imaging and intraoperative detection of 
sentinel lymph node (SLN) in the breast cancer, 
prostate cancer, malignant melanoma, and carcinomas 
of vulvar, penile, and head and neck squamous cell. 
Imaging of regional lymphatic flow for individualised 
radiotherapy and lymphatic flow scintigraphy are 
performed for diagnosing lymphatic oedema in the 
limbs. It is also used in digestive exploration; 
gastroesophageal imaging. Subcutaneous injection is 
route of administration of 99mTc-colloidal rhenium 
sulphide, generally in the interdigital space of the hand 
or foot, or in the marginal area of a tumour. 
Since colloids are made of small size, they can be 
rapidly taken up from interstitial fluids into the lymph 
capillaries having a discontinuous wall with pores and 
no basal membrane. Some of the colloidal particles are 
phagocytosed by bordering cells of the 
reticuloendothelial system during transport of the lymph 
through the lymph nodes. This process is repeated 
from one lymph node to the next lymph node. It is a 
metal colloid, which is partly phagocytosed and stored 
in the first lymph node group. Following administration, 
the radioactivity in the lymph node corresponds to 3.06 
± 0.10 % of the injected radioactivity at the first hour, 
and 3.83 ± 0.16 % at the third hour [177]. Rhenium 
sulphide nanocolloid comprises of two vials. One 
contains: Rhenium (as sulphide): 0.15 mg; Gelatin: 9.6 
mg; Ascorbic acid: 7 mg; Water for injection: 1 mL, 
whereas second vial contains: Sodium pyrophosphate: 
3 mg; Stannous chloride dihydrate: 0.1 mg [178].  
99mTc-Sn colloid has been used for liver and spleen 
scintigraphy [179, 180]. When injected, 99mTc colloidal 
tin circulates in the blood and accumulates in the liver 
and the spleen. An image will then help doctor to 
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determine the ability of these organs to eliminate 
foreign material like bacteria and denatured protein 
from the blood. 
The particle size of 99mTc-tin colloid is dependent on 
the ratio between the 99mTc solution and the tin solution 
[181]. As the ratio of tin decreases, the size of colloidal 
particles increases. Technetium-99m-tin colloid has a 
particle size of 50–1500 nm. Uenosono et al. 
recommended 100 nm as a suitable colloidal size for 
detecting SLN in gastric cancer [182]. Formulation of 
tin colloid kit generally contains, Stannous chloride 
dihydrate: 0.3 mg, Sodium fluoride: 1.0 mg, Sodium 
chloride: 3.6 mg, and Povidone: 0.5 mg [183]. 
2.22.3. 99mTc-Pertechnetate  
Sodium pertechnetate (Na99mTcO4) solution is used 
in adults for imaging of brain including cerebral 
radionuclide angiography; thyroid, salivary gland, 
placenta localization; blood pool including radionuclide 
angiography and urinary bladder. In children 
Na99mTcO4 injection is used for imaging purposes of 
brain including cerebral radionuclide angiography; 
thyroid, blood pool including radionuclide angiography 
and urinary bladder; direct isotopic cystography for the 
detection of vesico-ureteral reflux [184, 184]. 
The 99mTcO4- ion distributes in the human body as 
the iodide ion, but is not organified when accumulated 
in the thyroid gland. It tends to accumulate in 
intracranial lesions with excessive neovascularity or an 
altered blood-brain barrier. It also accumulates in the 
thyroid/salivary glands, gastric mucosa, and choroid 
plexus. The 99mTcO4- ion is released unchanged from 
the thyroid gland. Since the 99mTcO4- ion remains in the 
circulatory system for sufficient time it can be used for 
blood pool measurement, organ perfusion, and major 
vessel studies. It gradually equilibrates with the extra 
vascular space and small fraction of 99mTcO4- ion is 
promptly excreted via the kidneys [178, 185]. 
Thyroid uptake and scintigraphy using 99mTc-
pertechnetate is faster with minimum exposure to 
patient. Use of pertechnetate is more advantageous 
than with 131I-iodide, since the 99mTc gives far better 
images quality [186]. 
When Na99mTcO4 is mixed with a tin compound, it 
binds to red blood cells and can therefore be used to 
scan disorder in circulatory system. It is useful to detect 
gastrointestinal bleeding sites. 
Pertechnetate-99mTc is actively accumulated and 
secreted by the mucoid cells of the gastric mucosa 
[187], and therefore, Na99mTcO4 is injected into the 
human body when looking for ectopic gastric tissue as 
is found in a Meckel's diverticulum with Meckel's Scans 
[188]  
2.22.4. 99mTc-Pyrophosphate 
99mTc-Pyrophosphate (99mTc- PYP) Injection is a 
bone imaging agent used to demonstrate areas of 
altered osteogenesis. It is also a cardiac imaging agent 
used as an adjunct in the diagnosis of acute myocardial 
infarction. 99mTc- PYP is given intravenously and 1-2 h 
post injection, an estimated 40-50 % of the injected 
dose had been taken up by the skeleton, and ~ 0.01-
0.02 %/g of acutely infarcted myocardium. In one hour, 
~ 11% remains in the vascular system, and after 24 h 
reduces to ~ 2-3 %. After 24 h post injection, the 
average urinary excretion was observed to be ~ 40 %. 
99mTc- PYP has been used as a blood pool imaging 
useful for gated blood pool imaging and for the 
detection of sites of gastrointestinal bleeding. When 
administered intravenously 15-30 minutes prior to 
intravenous injection of Na99mTcO4 for in vivo red blood 
cell labeling, ~ 75% of the injected radioactivity is found 
in the blood pool. The modified in vivo/in vitro red blood 
cell labeling method has also been utilized for blood 
pool imaging [189, 190]. 
2.23. Thallium-201 
Thallium-201 (201Tl) has a physical half-life of 73.1 
h, and decays by EC to mercury-201 (201Hg). Useful 
Photons for the detection/imaging are 135.3 KeV 
(2.7%) and 167.4 KeV (10 %). The 201Hg daughter of 
201Tl emits lower energy x-rays that are recommended 
for myocardial imaging, because the mean percent 
disintegration at 68.9 to 80.3 keV is much higher than 
the combination of other gammas mean percent 
disintegration. 
High-energy protons are used for the production of 
thallium-201. Several methods have been investigated 
for production of 201Tl. 
1. 202Hg (p, 2n) 201Tl (proton energy 50→14 MeV) 
2. natHg (p, xn) 201Tl (proton energy 50→14 MeV) 
3.  203Tl (p, 3n)201Pb --------- → 201Tl (proton energy 
28→20 MeV) 
4. 206Pb (p,x) 201Tl (proton energy 60→15 MeV) 
5. Pb, Bi (p, spall)201Tl (proton energy 800 MeV)  
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The most common route however is the 203Tl (p, 3n) 
201Pb → 201Tl reaction on enriched 203Tl. The optimum 
proton energy range for production is 28 →20 MeV, 
Therefore a medium-energy 30 MeV proton is needed. 
The production of no-carrier-added 201Tl via irradiation 
of 203Tl or natTl involves a 2-step process and complex 
wet chemical processing. At first 201Pb is separated 
from the target matrix activity. Thereafter 201Pb is 
allowed to decay for an optimum time of 32 h whereby 
201Tl grows in. The removal of the 201Tl can be 
performed by anion-exchange chromatography or 
solvent extraction techniques [191].  
Thallous chloride (201Tl) is indicated in myocardial 
perfusion imaging for the diagnosis and localization of 
myocardial infarction [192-195]. 
Thallous chloride (201Tl) is also indicated in studies 
of myocardial perfusion done under resting conditions 
and after physiologic or pharmacologic stress induced 
by exercise or infusion of dipyridamole, adenosine, or 
dobutamine respectively, to detect myocardium with 
abnormal perfusion reserve secondary to coronary 
artery disease [196-200].  
Thallous chloride (201Tl) is used for the detection 
and localization of parathyroid tissue in patients with 
documented hyperparathyroidism. Thallous chloride 
(201Tl) may also be useful in preoperative screening to 
localize extrathyroidal and mediastinal sites of 
parathyroid tissue and for postsurgical reexamination 
[201-203]. However, the use of thallous chloride (201Tl) 
as a parathyroid imaging agent generally has been 
replaced by technetium Tc-99m sestamibi. 
Thallous chloride (201Tl) is used for the detection 
and localization of various tumors, including thyroid 
carcinomas, malignant brain neoplasms, lymphomas, 
and mediastinal tumors, especially for postoperative 
detection of residual and recurrent tumors and 
differentiation of these from post-therapy fibrosis or 
necrosis [204-208]. 
Usual adult and adolescent administered activity 
(IV) are 37-74 MBq (1-2 mCi) and 74-148 MBq (2-4 
mCi) for Planar and SPECT imaging, respectively. 
Parathyroid imaging is performed by injecting 75 MBq 
(2 mCi) and tumor imaging by 55.5 -111 MBq(1.5-3 
mCi)  Usual pediatric administered activity for Cardiac 
imaging andParathyroid imaging is1.11 MBq (30 µCi) 
per kg of body weight administered intravenously, with 
a minimum total dosage of 27.75 MBq (750 µCi) and a 
maximum total dosage of 111 MBq (3 mCi). 
In Cardiac imaging, the Thallous chloride (201Tl) 
appears to accumulate in cells of myocardium and 
other tissues in a manner analogous to that of 
potassium [209]. The initial biodistribution of Thallous 
chloride (201Tl) in most tissues is primarily related to 
regional blood flow. Ischemic myocardial cells take up 
less 201Tl than nonischemic cells, in proportion to the 
relative change [202, 203] in blood flow, especially 
during maximal stress (or pharmacologically induced 
vasodilation) when the differential in perfusion is most 
marked between regions supplied by normal coronary 
arteries and those supplied by stenotic vessels. 
Imaging equipment can record regional differences in 
thallium-201 uptake, and thus in myocardial perfusion, 
confirming the presence or absence of coronary 
disease [210, 211] 
In Parathyroid imaging, the Thallous chloride (201Tl) 
localizes in parathyroid adenomas, parathyroid 
hyperplasia, and other abnormal tissues, generally in 
proportion to organ blood flow at the time of injection 
[212]. 
Two other Technetium-99m labeled compounds 
MIBI and tetrofosmin are also used for same purpose. 
Usually MIBI/tetrofosmin labeled with 10-30 mCi of 
technetium-99m is injected to patient.99mTc-MIBI / 
99mTc-tetrofosmin requires two injections, a stress study 
and a rest study. While only one injection of (~2mCi) 
201TlCl is sufficient for whole study. However images 
are inferior compared to 99mTc-MIBI / 99mTc-tetrofosmin 
[213]. 
2.24. Yttrium-90 
Yttrium-90 (90Y) has physical half-life is 2.7 days. It 
emits a β- particle with a maximum energy of 2.27 
MeV, a mean energy of 0.935 MeV and an average 
soft tissue penetration range of 3.6 mm. The low 
specific activity 90Y is produced in a nuclear reactor by 
neutron activation of the non-radioactive 89Y, where 89Y 
captures a neutron and becomes the radioactive β-
emitter 90Y [214]. For very high specific activity 90Y (that 
is used for target therapy), a radionuclide generator 
system of Strontium-90 (90Sr) is used and it is based on 
the fact that 90Sr decays to 90Y [215]. Various types of 
90Sr/90Y generators have been developed including ion 
exchange based generator, Supported Liquid 
Membrane (SLM) based generator and 
Electrochemical generator. The best of these 
generators is the electrochemical system as it yields 
around 97–98% of 90Y deposition [216-218]. 
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Finally, for patients with rheumatoid arthritis (RA) 
that is unresponsive to glucocorticoids, nonsteroidal 
anti-inflammatory pharmaceuticals and disease-
modifying antirheumatoid pharmaceuticals, cronicoligo 
or mono-arthritis can be cured by radionuclide 
synovectomy. Radiosynoviorthesis with 90Y is an 
established concept for the treatment of persistent 
synovitis of the knee joint [219, 220]. 
Radiolabeled particles of various sizes have been 
applied for delivering a high localized radiation dose to 
tumors in different organs following intraarterial 
administration for more six decades [221]. Delivery of a 
highly selected distribution of radiation doses that are 
20-30 times greater than that achievable by external 
beam therapy is possible by virtue of the preferential 
blood flow to the tumor relative to normal tissues [222]. 
Different types of particles and microspheres have 
been utilized including 90Y-labeled-Y2O3 particles, 90Y-
ceramic microspheres, 90Y-resin microsphere and 90Y 
glass microsphere [223, 224]. 
TheraSphere consists of insoluble glass 
microspheres where 90Y is an integral part of the glass 
[224]. The mean diameter of spheres ranges from 20-
30 µm. Each mg of radiopharmaceutical contains 
between 22 000 and 73 000 microspheres. Hepatic 
artery radioembolization (RE) with 90Y-loaded 
microspheres is an alternative treatment for patients 
with unresectable primary or secondary liver tumours, 
especially in cases of hepatocellular carcinoma (HCC) 
and metastatic colorectal cancer (mCRC) [224].  
Yttrium [90Y] silicate injection is a suspension for 
injection for intra-articular or intra-cavitary use. The 
active ingredient, yttrium [90Y] silicate is present as a 
sterile colloidal suspension in water for injection. The 
solution also contains sodium silicate, and is buffered 
with hydrochloric acid to give a pH of 10.0 - 11.5. Each 
mL of solution contains yttrium: 0.24 - 0.39 mg/ml. The 
radioactive concentration is 92.5 - 370 MBq/ml (2.5 - 10 
mCi/ml) and the specific activity is 259-1259 MBq/mg 
(7-35 mCi/mg) yttrium at reference time. Indications are 
therapeutic irradiation of synovial hypertrophy of the 
knee joints (isotopic radiation synovectomy) mainly for 
mono- or oligo-articular arthritis of chronic inflammatory 
rheumatism particularly rheumatoid polyarthritis. 
Yttrium [90Y] silicate is also used for treatment of 
recurrent malignant effusions in those patients who 
have failed to respond to conventional radiation therapy 
or chemotherapy of the pleural and peritoneal cavities. 
The recommended injected radioactivity ranges from 
111-222 MBq (3-6 mCi) per joint. Several radiation 
synovectomies can be performed successively as well 
as simultaneously. Reinjection of radioactive Yttrium 
[90Y] silicate colloid in one articulation can be 
performed after a period of 6 months in the event of 
relapse. The activity per administration typically ranges 
from 400 MBq to 3000 MBq (10.8 - 81.1 mCi) of 90Y 
depending on clinical indication. Yttrium [90Y] silicate 
Injection of colloid can be given via intra-articular, 
intrapleural or intraperitoneal [225]. Yttrium-90 
hydroxyapatite is commercially available as a 
therapeutic agent to cure chronic kneesynovitisin 
rheumatoid arthritis, hemophilia or orthopedic troubles 
[142]. 
2.25. Xenon-133 
Xenon-133 (133Xe) has a half-life of 5.245 d and it 
disintegrates by β- and γ emissions. The photon of 81 
keV finds application in detection and imaging studies. 
Xenon-133 is produced by fission of Uranium-235 
[226]. Xenon-133 gas has been shown to be useful for 
diagnostic inhalation studies for the evaluation of 
pulmonary function, for lungs scanning and applied to 
assessment of cerebral blood flow. 
Xenon-133 is a readily diffusible gas which is not 
utilized by the body. It passes through cell membranes, 
freely exchanges between blood and tissue, and tends 
to concentrate more in body fat than in blood, plasma, 
water or protein solutions. Xenon-133 gas is 
administered by inhalation from a spirometer or closed 
respirator device. The usual activity range employed for 
inhalation by an average patient of 70 kg is 74 to 1110 
MBq (2 to 30 mCi) for pulmonary function including 
imaging and 370 to 1110 MBq (10 to 30 mCi) for 
cerebral blood flow studies [227, 228]. 133Xe is 
historically an agent that was used for ventilation 
studies [229].  
CONCLUSIONS 
Sodium iodide (131I) treatment of thyroid disorders is 
the only treatment that has continued to be developed 
up to the present day and has become fully established 
in routine clinical practice in developing as well as in 
developed countries. Some other radionuclides, such 
as 22Na, 35S, 59Fe, 85Sr, radioindium and 198Au find rare 
medical applications in routine. Use of radioactive 
sealed sources (60Co, 192Ir and short lived 
radionuclides) will continue to play their important role 
in medical applications and even increase in the future. 
In the wake of the terrorist attack on September 11th 
2001 in USA, there is a security concern over sealed 
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sources of cesium-137 as CsCl especially susceptible 
to be being used by terrorists. Its substitution by less 
hazardous technology as well as use of stable 
compound of 137Cs is also recommended. 
Nanoparticles and nanocomposites, containing 
radioactive isotopes, are promising objects for a series 
of biomedical and chemical applications. Use of 
currently inorganic radioactive compounds will continue 
in near future and new compounds of 47Sc, 64Cu, 
67Cu,!05Rh, 111Ag, 153Sm, 165Dy,166Ho,177Lu and 199Au 
may emerge, particularly in the field of radiotherapy. 
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